Long Non-Coding RNAs: Tools for Understanding and Targeting Cancer Pathways

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Oct 14

PMID 36230680

Authors

Gaurav Kumar Pandey

Chandrasekhar Kanduri

Affiliations

Soon will be listed here.

Abstract

The regulatory nature of long non-coding RNAs (lncRNAs) has been well established in various processes of cellular growth, development, and differentiation. Therefore, it is vital to examine their contribution to cancer development. There are ample examples of lncRNAs whose cellular levels are significantly associated with clinical outcomes. However, whether these non-coding molecules can work as either key drivers or barriers to cancer development remains unknown. The current review aims to discuss some well-characterised lncRNAs in the process of oncogenesis and extrapolate the extent of their decisive contribution to tumour development. We ask if these lncRNAs can independently initiate neoplastic lesions or they always need the modulation of well characterized oncogenes or tumour suppressors to exert their functional properties. Finally, we discuss the emerging genetic approaches and appropriate animal and humanised models that can significantly contribute to the functional dissection of lncRNAs in cancer development and progression.

Citing Articles

Analysis of expression characteristics of ferroptosis-related lncRNAs in gastrointestinal cancer patients in Asia.

Ding N, Kang Y, Tan X, Tang Y, Zhang Y, He Y Discov Oncol. 2025; 16(1):306.

PMID: 40072763 PMC: 11904047. DOI: 10.1007/s12672-024-01733-3.

Tissue factor pathway inhibitor-2 (TFPI-2)-an underappreciated partaker in cancer and metastasis.

Wojtukiewicz M, Mysliwiec M, Tokajuk A, Kruszewska J, Politynska B, Jamroze A Cancer Metastasis Rev. 2024; 43(4):1185-1204.

PMID: 39153052 PMC: 11554837. DOI: 10.1007/s10555-024-10205-7.

Basement Membrane-Associated lncRNA Risk Model Predicts Prognosis and Guides Clinical Treatment in Clear Cell Renal Cell Carcinoma.

Li X, Kuang Q, Peng M, Yang K, Luo P Biomedicines. 2023; 11(10).

PMID: 37893009 PMC: 10604562. DOI: 10.3390/biomedicines11102635.

in Serum Extracellular Vesicles Reflects Resistance to AR Axis-targeted Therapy Among CRPC Patients.

Kato T, Kawakami K, Mizutani K, Ando T, Sakai Y, Sakurai K Cancer Genomics Proteomics. 2023; 20(5):456-468.

PMID: 37643783 PMC: 10464938. DOI: 10.21873/cgp.20397.

Long Non-Coding RNA ZSCAN16-AS1 Promotes the Malignant Progression of Melanoma Through Regulating the miR-503-5p/ARL2 Axis.

Zhao Y, Zhang X, Wang J, Li Y, Wu Y, Liu J Clin Cosmet Investig Dermatol. 2023; 16:1821-1831.

PMID: 37483470 PMC: 10361287. DOI: 10.2147/CCID.S407323.

References

Katsushima K, Natsume A, Ohka F, Shinjo K, Hatanaka A, Ichimura N . Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun. 2016; 7:13616. PMC: 5150648. DOI: 10.1038/ncomms13616. View

Tang J, Zhong G, Zhang H, Yu B, Wei F, Luo L . LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA. Cell Death Dis. 2018; 9(12):1167. PMC: 6281578. DOI: 10.1038/s41419-018-1220-7. View

Dhanasekaran R, Deutzmann A, Mahauad-Fernandez W, Hansen A, Gouw A, Felsher D . The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2021; 19(1):23-36. PMC: 9083341. DOI: 10.1038/s41571-021-00549-2. View

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

Mitra S, Muralidharan S, Di Marco M, Juvvuna P, Thankaswamy Kosalai S, Reischl S . Subcellular Distribution of p53 by the p53-Responsive lncRNA Determines Chemotherapeutic Response in Neuroblastoma. Cancer Res. 2020; 81(6):1457-1471. DOI: 10.1158/0008-5472.CAN-19-3499. View

Tavares R, Pyle A, Somarowthu S . Phylogenetic Analysis with Improved Parameters Reveals Conservation in lncRNA Structures. J Mol Biol. 2019; 431(8):1592-1603. PMC: 6515926. DOI: 10.1016/j.jmb.2019.03.012. View

Sarropoulos I, Marin R, Cardoso-Moreira M, Kaessmann H . Developmental dynamics of lncRNAs across mammalian organs and species. Nature. 2019; 571(7766):510-514. PMC: 6660317. DOI: 10.1038/s41586-019-1341-x. View

Pedram Fatemi R, Salah-Uddin S, Modarresi F, Khoury N, Wahlestedt C, Faghihi M . Screening for Small-Molecule Modulators of Long Noncoding RNA-Protein Interactions Using AlphaScreen. J Biomol Screen. 2015; 20(9):1132-41. PMC: 4576503. DOI: 10.1177/1087057115594187. View

Liu Y, Cao Z, Wang Y, Guo Y, Xu P, Yuan P . Genome-wide screening for functional long noncoding RNAs in human cells by Cas9 targeting of splice sites. Nat Biotechnol. 2018; . DOI: 10.1038/nbt.4283. View

10.

Li G, Kryczek I, Nam J, Li X, Li S, Li J . LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol. 2021; 23(5):526-537. PMC: 8122078. DOI: 10.1038/s41556-021-00672-3. View

11.

Zhu S, Li W, Liu J, Chen C, Liao Q, Xu P . Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol. 2016; 34(12):1279-1286. PMC: 5592164. DOI: 10.1038/nbt.3715. View

12.

Chen F, Chen J, Yang L, Liu J, Zhang X, Zhang Y . Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol. 2019; 21(4):498-510. DOI: 10.1038/s41556-019-0299-0. View

13.

Diederichs S . The four dimensions of noncoding RNA conservation. Trends Genet. 2014; 30(4):121-3. DOI: 10.1016/j.tig.2014.01.004. View

14.

Chen L, Qian X, Wang Z, Zhou X . The HOTAIR lncRNA: A remarkable oncogenic promoter in human cancer metastasis. Oncol Lett. 2021; 21(4):302. PMC: 7905531. DOI: 10.3892/ol.2021.12563. View

15.

Grossi E, Sanchez Y, Huarte M . Expanding the p53 regulatory network: LncRNAs take up the challenge. Biochim Biophys Acta. 2015; 1859(1):200-8. DOI: 10.1016/j.bbagrm.2015.07.011. View

16.

Akhade V, Pal D, Kanduri C . Long Noncoding RNA: Genome Organization and Mechanism of Action. Adv Exp Med Biol. 2017; 1008:47-74. DOI: 10.1007/978-981-10-5203-3_2. View

17.

Vancura A, Lanzos A, Bosch-Guiteras N, Torres Esteban M, Gutierrez A, Haefliger S . Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs. NAR Cancer. 2021; 3(2):zcab013. PMC: 8210278. DOI: 10.1093/narcan/zcab013. View

18.

Hu X, Feng Y, Zhang D, Zhao S, Hu Z, Greshock J . A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell. 2014; 26(3):344-357. PMC: 4159613. DOI: 10.1016/j.ccr.2014.07.009. View

19.

Lemos A, da Rocha Matos A, Ferreira L, Gimba E . The long non-coding RNA : an update of its functions and clinical applications as a biomarker in prostate cancer. Oncotarget. 2019; 10(61):6589-6603. PMC: 6859920. DOI: 10.18632/oncotarget.27284. View

20.

Farnebo M, Bykov V, Wiman K . The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun. 2010; 396(1):85-9. DOI: 10.1016/j.bbrc.2010.02.152. View